Cancer Science · 2011 · 35 citations · 38 references
MedicineOncologyPharmacologyCancer PharmacologyMolecular OncologyRadiobiologyBiological Effects Of RadiationHypoxia AdaptationOxygen EffectRadiation TherapyCancer Cell RadiosensitivityHypoxia RadiosensitivityHypoxia-mediated ResistanceNitric OxideNon-small Cell Lung Cancer TherapyNon-small Cell Lung Cancer TreatmentTherapeutic RadiosensitizationTyrosine Kinase Inhibitor Therapy
The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (E-TKI) resistance has emerged as an important clinical issue. To overcome this resistance, researchers have examined different modalities, either for use as a monotherapy or in combination with E-TKI therapy. In the present study, we investigated whether a decrease in nitric oxide (NO) levels affects the radiosensitization of non-small cell lung cancer (NSCLC) cell lines. A549 and H3255 NSCLC cells were examined. They were subjected to hypoxic conditions and monotherapy, or combined therapy using radiation and N(G) -monomethyl-l-arginine, monoacetate (LNMMA). Reductions in nitric oxide levels enhanced the radiosensitivity of both cell lines and significantly reduced the expression of both hypoxia-inducible factor-1α (HIF-1α) and EGFR in H3255 cells compared to A549 cells. Since NO is significantly associated with cell metabolism, we measured the levels of pyruvate dehydrogenase kinase-1 (PDK-1), reactive oxygen species, and oxygen and observed that the expression of PDK-1 was significantly reduced. This reduction was seen simultaneously after the silencing of HIF-1α; however, not following LNMMA treatment. The oxygen concentration was significantly increased in the treated cells, and their viability decreased in parallel. Reactive oxygen species were decreased after LNMMA and radiation treatment. Adding EGFR-TKI to cells with reduced NO levels further suppressed cell viability when combined with radiation. This study suggests that a reduction in the NO level might substantially overcome the radioresistance of mutant NSCLC cells.
38
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
J. Guillermo Paez, Pasi A. Jänne, Jeffrey C. Lee et al. · Science · 2004 · 9.4K citations
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
James A. Bonner, Paul M. Harari, J. Giralt et al. · New England Journal of Medicine · 2006 · 5.1K citations · Full text
<i>EGFR</i> Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Susumu Kobayashi, Titus J. Boggon, Tajhal Dayaram et al. · New England Journal of Medicine · 2005 · 3.9K citations · Full text
Medicine, Oncology, Pharmacology +15